The Role of PPARs in Cancer

被引：195

作者：

Tachibana, Keisuke ^{[1
]}

Yamasaki, Daisuke ^{[1
,2
]}

Ishimoto, Kenji ^{[1
,3
]}

Doi, Takefumi ^{[1
,2
,3
]}

机构：

[1] Osaka Univ, Grad Sch Pharmaceut Sci, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan

[3] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan

来源：

PPAR RESEARCH | 2008年 / 2008卷

关键词：

D O I：

10.1155/2008/102737

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily. PPAR alpha is mainly expressed in the liver, where it activates fatty acid catabolism. PPAR alpha activators have been used to treat dyslipidemia, causing a reduction in plasma triglyceride and elevation of high-density lipoprotein cholesterol. PPAR delta is expressed ubiquitously and is implicated in fatty acid oxidation and keratinocyte differentiation. PPAR delta activators have been proposed for the treatment of metabolic disease. PPAR gamma 2 is expressed exclusively in adipose tissue and plays a pivotal role in adipocyte differentiation. PPAR gamma is involved in glucose metabolism through the improvement of insulin sensitivity and represents a potential therapeutic target of type 2 diabetes. Thus PPARs are molecular targets for the development of drugs treating metabolic syndrome. However, PPARs also play a role in the regulation of cancer cell growth. Here, we review the function of PPARs in tumor growth. Copyright (C) 2008 Keisuke Tachibana et al.

引用

页数：15

共 195 条

[1] Adipocyte-type fatty acid-binding protein as inter-compartmental shuttle for peroxisome proliferator activated receptor γ agonists in cultured cell [J].

Adida, A ;

Spener, F .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2006, 1761 (02) :172-181

[2] MECHANISTICALLY-BASED HUMAN HAZARD ASSESSMENT OF PEROXISOME PROLIFERATOR-INDUCED HEPATOCARCINOGENESIS [J].

ASHBY, J ;

BRADY, A ;

ELCOMBE, CR ;

ELLIOTT, BM ;

ISHMAEL, J ;

ODUM, J ;

TUGWOOD, JD ;

KETTLE, S ;

PURCHASE, IFH .

HUMAN & EXPERIMENTAL TOXICOLOGY, 1994, 13 :S1-S117

[3] Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer [J].

Barak, Y ;

Liao, D ;

He, WM ;

Ong, ES ;

Nelson, MC ;

Olefsky, JM ;

Boland, R ;

Evans, RM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (01) :303-308

[4] PPARδ:: a dagger in the heart of the metabolic syndrome [J].

Barish, GD ;

Narkar, VA ;

Evans, RM .

JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (03) :590-597

[5]

BAYLY AC, 1993, J CELL SCI, V104, P307

[6] SUPPRESSION OF LIVER-CELL APOPTOSIS IN-VITRO BY THE NONGENOTOXIC HEPATOCARCINOGEN AND PEROXISOME PROLIFERATOR NAFENOPIN [J].

BAYLY, AC ;

ROBERTS, RA ;

DIVE, C .

JOURNAL OF CELL BIOLOGY, 1994, 125 (01) :197-203

[7] Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation [J].

Betz, MJ ;

Shapiro, I ;

Fassnacht, M ;

Hahner, S ;

Reincke, M ;

Beuschlein, F .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (07) :3886-3896

[8] USE OF PRIMARY CULTURES OF ADULT-RAT HEPATOCYTES TO INVESTIGATE MECHANISMS OF ACTION OF NAFENOPIN, A HEPATOCARCINOGENIC PEROXISOME PROLIFERATOR [J].

BIERI, F ;

BENTLEY, P ;

WAECHTER, F ;

STAUBLI, W .

CARCINOGENESIS, 1984, 5 (08) :1033-1039

[9] Targeted induction of apoptosis for cancer therapy: current progress and prospects [J].

Bremer, Edwin ;

van Dam, Go ;

Kroesen, Bart Jan ;

de Leij, Lou ;

Helfrich, Wijnand .

TRENDS IN MOLECULAR MEDICINE, 2006, 12 (08) :382-393

[10] Activation of PPARγ leads to inhibition of anchorage-independent growth of human colorectal cancer cells [J].

Brockman, JA ;

Gupta, RA ;

DuBois, RN .

GASTROENTEROLOGY, 1998, 115 (05) :1049-1055

← 1 2 3 4 5 6 7 8 9 10 →